Neogenomics (NEO) Current Deferred Revenue (2017 - 2026)

Neogenomics (NEO) has reported Current Deferred Revenue for 10 consecutive years, with $899000.0 the latest figure, recorded in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $899000.0, down 38.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $899000.0 (down 38.51% YoY), and the FY2025 annual result was $1.2 million, up 202.44% from the prior year.
• Current Deferred Revenue was $899000.0 for Q1 2026 at Neogenomics, down from $1.2 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $7.6 million in Q4 2022 and troughed at $409000.0 in Q4 2024.
• Average Current Deferred Revenue over 5 years is $3.2 million, with a median of $1.6 million recorded in 2025.
• Year-over-year, Current Deferred Revenue plunged 83.72% in 2024 and soared 202.44% in 2025.
• Over 5 years, Current Deferred Revenue stood at $7.6 million in 2022, then plunged by 71.81% to $2.1 million in 2023, then plunged by 80.8% to $409000.0 in 2024, then jumped by 202.44% to $1.2 million in 2025, then fell by 27.32% to $899000.0 in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $899000.0 in Q1 2026, $1.2 million in Q4 2025, and $1.6 million in Q3 2025.